6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer (related to financial reporting)
EFFECT: Others
424B3: Prospectus
CORRESP: CORRESP
UPLOAD: Others
DEL AM: Others
F-3: Registration statement for specified transactions by certain foreign private issuers
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
SILENCE THERAPEUTICS PLC | 6-K: Report of foreign private issuer (related to financial reporting)
SILENCE THERAPEUTICS PLC | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Richard Ian Griffiths(16.9%),Ora Capital Limited(7.8%)
SILENCE THERAPEUTICS PLC | 20-F: Registration statement / Annual report / Transition report
SILENCE THERAPEUTICS PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
SILENCE THERAPEUTICS PLC | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
SILENCE THERAPEUTICS PLC | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lombard Odier Asset Management (USA) Corp(10.4%)
SILENCE THERAPEUTICS PLC | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(5.43%),Deep Track Biotechnology Master Fund, Ltd.(5.43%), etc.
No Data